 |
|
|
| |
Efficacy and safety of TMC278 in treatment-naïve, HIV-1-infected patients with HBV/HCV co-infection enrolled in the Phase III ECHO and THRIVE trials
|
| |
| |
Reported by Jules Levin
Glasgow 2010 Nov 7-11
Mark Nelson,1 Gerardo Amaya,2 Nathan Clumeck,3 Clovis Arns da Cunha,4 Dushyantha Jayaweera,5 Patrice Junod,6 Li Taisheng,7 Pablo Tebas,8 Marita Stevens,9 Annemie Buelens,9 Simon Vanveggel,9 Katia Boven10
1Chelsea and Westminster Hospital, London, UK; 2Centro Médico Puerta de Hierro, Zapopan, Jalisco, Mexico; 3Saint-Pierre University Hospital, Brussels, Belgium; 4Centro Médico São Francisco, Curitiba, Brazil; 5University of Miami, Miami, FL, USA; 6Clinique Medicale du Quartier Latin, Montreal, Canada;7Beijing PUMC Hospital, Beijing, China; 8University of Pennsylvania, Philadelphia, PA, USA; 9Tibotec BVBA, Beerse, Belgium; 10Tibotec Inc., Titusville, NJ, USA
|
| |
|
|
|
|
|
